Shamburg News · 8-K filed Oct 1, 2026, 7:57 AM EDT
Nektar Therapeutics Reports 52-Week Rezpegaldesleukin Data in Alopecia Areata and Atopic Dermatitis
NKTR · NEKTAR THERAPEUTICS
- Other event
- Reg FD disclosure
- Materiality: medium
On October 1, 2026, Nektar Therapeutics furnished a press release and presentation reporting long-term data from its Phase 2b REZOLVE-AA and REZOLVE-AD studies of rezpegaldesleukin, presented at the EADV Congress 2026. In alopecia areata, SALT Score ≤20 responses were maintained in 75% of patients at 4 months and 63% at 6 months off treatment, and SALT Score ≤10 responses rose from 7% to 19%. The company also stated that a third Phase 3 atopic dermatitis study has been initiated and the Phase 3 ZENITH AA study is planned to start in early 2027.
Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001213900-26-105453.
Written from the filing by Shamburg Markets. Figures are as reported by the company.